

October 7, 2026

**Re: Docket No. USTR-2026-0529 — 2026 Review of Notorious Markets for Counterfeiting and Piracy:
Comment Request**

To Whom It May Concern:

Thank you for considering these comments, prepared by the Alliance for Safe Online Pharmacies (ASOP) Global to ensure patient access to safe and legitimate online pharmacies in accordance with applicable laws. ASOP Global is currently active in the United States, Canada, and Europe.

Observations: Americans Are Vulnerable to Counterfeit Medicines

ASOP Global appreciates the United States Trade Representative's (USTR) continued efforts to address online counterfeit markets and the health and safety risks associated with intellectual property rights violations.

The rise of rogue online drug sellers globally is not only a threat to intellectual property (IP) rights but also a major public health issue. Sellers engaged in IP violations often put public health at risk by operating in violation of state and federal law, such as selling unapproved or counterfeit drugs, not requiring a valid prescription, and failing to be appropriately licensed in the jurisdictions where patients are located.

For nearly two decades, the National Association of Boards of Pharmacy (NABP), the nonprofit association of U.S. state pharmacy regulators, has systematically reviewed websites selling prescription drugs to U.S. consumers. Across every published review from 2011 through 2017, covering between 8,000 and 11,700 websites, NABP consistently found that 95 to 97 % operated out of compliance with state and federal law or pharmacy practice standards.¹ NABP's Not Recommended List now exceeds 40,000 domain names, none operated by a pharmacy licensed in any U.S. state.² Independent peer-reviewed research confirms the problem is current and acute: a 2024 study found that 42% of online-pharmacy search results for semaglutide led to illegal sellers, and all products test-purchased from them were probable substandard or falsified medicines.³

¹ NABP, Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators, July 2016 (95.79% of 11,299 sites reviewed); *see also id.* (Aug. 2017) (95.8% of 11,688). Available at: https://nabp.pharmacy/wp-content/uploads/2016/07/NABP-Internet-Drug-Outlet-Report_Oct2012.pdf

² National Association of Boards of Pharmacy, Rogue Rx Activity Report: Disrupting Illegal Online Pharmacies: Lock-and-Suspend as a Tool to Protect Patients, 2022. Available at: <https://nabp.pharmacy/wp-content/uploads/2022/10/Rogue-Rx-Activity-Report-Disrupting-Illegal-Online-Pharmacies-2022.pdf>

³ Ashraf et al, Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study, 2024, *Journal of Medical Internet Research*. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC11582493/>

Consumer Behavior and Perceptions

The rapid expansion of technology, telehealth, and global events such as the COVID-19 pandemic has normalized online purchasing of prescription drugs.⁴ ASOP Global Foundation's 2025 national survey of 1,501 U.S. adults found 38% of U.S. adults have purchased prescription medicines online, with 55% now buying all or most of their prescriptions online.⁵ But this growth has come at a cost: 27% of online purchasers report having received counterfeit or substandard medicine or being harmed by medicine purchased online—up from 24% in 2023.⁶ Perceived risk has surged accordingly, with 66% of U.S. adults now considering online purchasing risky – a 22-percentage-point increase from 2023. Yet dangerous misconceptions persist: 65% of U.S. adults falsely believe that all websites offering prescription medicines online are reviewed or approved by FDA or state regulators, and 51% falsely believe that only safe, verified sellers appear on the first page of search results.⁷ Perhaps most concerning, many consumers knowingly trade safety for affordability: 33% of online purchasers would continue buying from an unlicensed source if it significantly improved cost, convenience, access, or privacy, and 40% say they would turn to unlicensed sources if healthcare costs rose sharply.⁸

Restrictions on access to prescription medications, whether due to policy barriers, drug shortages, inconvenience, or costs, drive consumers to seek alternative options online.⁹ Unfortunately, consumers are not always directed to safe, compliant online pharmacies; instead, Americans too often encounter illegal online drug sellers. These unregulated enterprises take advantage of the public's desperation and illegally sell drugs to respond to consumer demand swiftly.

The Counterfeit Crisis: Lifestyle and Lifesaving Drugs

No therapeutic category is immune from drug counterfeiters. Take, for example, two distinct therapeutic areas: GLP-1 receptor agonists and oncology medications:

GLP-1 receptor agonists ("GLP-1s")

Among Americans who have taken a GLP-1 medication, 25% have purchased one online.¹⁰ But the harms are stark: 40% of online GLP-1 purchasers report having received counterfeit or substandard medicine or being harmed – nearly double the rate reported by purchasers of other medications. Much of this harm traces to consumer confusion.¹¹ More than 85% of online GLP-1 purchasers falsely believe that compounded medications are evaluated by the FDA for safety and efficacy, and 57% incorrectly believe compounded medications are the same as generics. This confusion is exploited: 74% of online GLP-1

⁴ Fittler et al, Attitudes and behaviors regarding online pharmacies in the aftermath of the COVID-19 pandemic: At a tipping point towards a new normal, 2022, *Frontiers in Pharmacology*. Available at:

<https://pmc.ncbi.nlm.nih.gov/articles/PMC9833114/>

⁵ ASOP Foundation, ASOP Global Foundation 2025 U.S. Consumer Behavior Summary, 2025. Available at:

<https://asopfoundation.pharmacy/wp-content/uploads/2025/11/ASOP-Foundation-2025-Consumer-Behavior-Survey.pdf>

⁶Id

⁷Id

⁸Id

⁹Id

¹⁰Id

¹¹Id

purchasers report buying compounded GLP-1s, and 56% report buying products marketed “for research purposes only.”¹²

The public health toll is measurable. In June 2026, America’s Poison Centers reported a 15-fold increase in GLP-1 exposure cases over the past five years, with compounded and research chemicals increasingly implicated in accidental overdoses.

And FDA’s enforcement record documents the scope of patient risk: warning letters to Empower Pharmacy (September 2026), US Chem Labs (February 2024), Synthetix Inc. d/b/a Helix Chemical Supply (February 2024), Summit Research Peptides (December 2024), USApeptide.com (February 2025), and Gram Peptides (March 2026) – all for selling unapproved semaglutide, tirzepatide, or similar products online, often under “research chemicals only” labeling.^{13,14,15,16,17,18} Further, in the most recent Empower Pharmacy warning letter, FDA identified “serious deficiencies” in Empower’s “practices for producing drug products, which put patients at risk.” The deficiencies included: failures in smoke studies, media fills, equipment maintenance, environmental monitoring, and production and process controls.¹⁹

Oncology Medications

Oncology medications present equally grave risks. A study of oncology drugs affected by shortages found that all shortage-listed medications were available online, approximately 75% of websites did not require prescriptions, and approximately 90% did not provide access to healthcare professionals.²⁰ A decade later, these drugs remain widely sold online through the same channels.

The common thread is clear: when patients cannot access medications through legitimate channels, they turn to online sources that put their health at risk. Tracking tools and enforcement must keep pace with this rapidly evolving threat.

AI and Emerging Technology Threats

Artificial intelligence is quickly changing the economics of pharmaceutical counterfeiting. AI-powered tools have dramatically lowered the barriers to creating sophisticated websites. Generative AI can now produce professional product descriptions, fabricated customer reviews, and fake verification badges, all

¹² Id

¹³ U.S. Food & Drug Administration, Warning Letter to Empower Clinic Services, LLC dba Empower Pharmacy, MARCS-CMS 738238 (Sept. 18, 2026). Available at: [fda.gov](https://www.fda.gov)

¹⁴ U.S. Food & Drug Administration, Warning Letter to Summit Research Peptides, MARCS-CMS 695607 (Dec. 10, 2024). Available at: [fda.gov](https://www.fda.gov)

¹⁵ U.S. Food & Drug Administration, Warning Letter to Helix Chemical Supply, MARCS-CMS 668918 (Feb. 7, 2024). Available at: [fda.gov](https://www.fda.gov)

¹⁶ U.S. Food & Drug Administration, Warning Letter to US Chem Labs, MARCS-CMS 669074 (Feb. 7, 2024). Available at: [fda.gov](https://www.fda.gov)

¹⁷ U.S. Food & Drug Administration, Warning Letter to USApeptide.com, MARCS-CMS 696885 (Feb. 26, 2025). Available at: [fda.gov](https://www.fda.gov)

¹⁸ U.S. Food & Drug Administration, Warning Letter to Gram Peptides, MARCS-CMS 721806 (Mar. 31, 2026). Available at: [fda.gov](https://www.fda.gov)

¹⁹ Supra note 13

²⁰ Fittler et al, A challenge for healthcare but just another opportunity for illegitimate online sellers: Dubious market of shortage oncology drugs, 2018. Available at: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6112670/>

at scale and at minimal cost. These sites are increasingly indistinguishable from legitimate pharmacies, and they are particularly dangerous for patients seeking high-value or life-sustaining medications who may be too desperate to scrutinize an unfamiliar source.

Consumers' growing reliance on AI tools compounds the problem. The EY US Consumer Health Survey 2026 found that 75% of U.S. respondents have requested or would consider requesting a test, treatment, or prescription based on search-engine results, 55% said the same about AI tools, and 76% view AI tools and search engines as reliable sources of health information.²¹ Bad actors exploit this trust. AI-driven campaigns now target consumers searching for medications through personalized social media ads, manipulated search results, and phishing emails, directing them to fraudulent pharmacies that mimic legitimate branded products.²²

The result is an enforcement mismatch. AI can generate new fraudulent websites faster than regulators can shut them down, and replacement sites deploy almost instantaneously. This represents a fundamental escalation in the threat landscape, requiring new approaches from USTR, law enforcement, and industry stakeholders.

New Evidence from Rx Watchdog & More

On September 15, 2026, the ASOP Global Foundation launched Rx Watchdog in partnership with S-3 Research. Unlike traditional point-in-time snapshots, Rx Watchdog is a public health monitoring platform that continuously monitors how prescription medicines, investigational new drugs, and emerging unapproved molecules are offered for sale by seemingly noncompliant sources across websites and social media. The platform focuses on high-risk therapeutic classes: metabolic disease products, including GLP-1s and investigational products like retatrutide, emerging molecules (like peptides), and cancer medicines.

The data is striking; in its first quarter of data collection alone, Rx Watchdog identified 41,496 product listings, 1,035 domains, and 1,751 social media posts offering prescription medications in monitored categories.²³

- **Unapproved investigational drugs are widely offered.** Rx Watchdog identified 1,906 listings offering retatrutide, an investigational drug not approved by FDA, despite regulatory warnings and extensive media coverage of the risks.

²¹ Torre, How GLP-1s, AI are changing the way consumers interact with healthcare, 2026. Available at: https://www.ey.com/en_us/insights/health/ey-us-consumer-health-survey-2026?

²² NABP, Rogue Rx Activity Report: Injectable Weight Loss Drugs: How Illegal Online Drug Sellers Are Taking Advantage of Patients, 2024. Available at: <https://nabp.pharmacy/wp-content/uploads/2024/04/RogueRx-Activity-Report-Injectable-Weight-Loss-Drugs-2024.pdf>

²³ ASOP Global Foundation, ASOP Global Foundation and S-3 Research Launch New Tool to Track Sellers Illegally Offering Noncompliant and High-Risk Medicines Online, 2026. Available at: <https://asopfoundation.pharmacy/wp-content/uploads/2026/09/ASOP-Rx-Watchdog-Release.pdf>

- **Peptides that cannot legally be compounded are widely available.** The initial scan found 20,983 product listings and 330 domains selling peptide molecules of emerging interest, such as MOTs-C, which cannot legally be compounded today.
- **Sellers span multiple therapeutic categories.** Rx Watchdog identified over 18,000 product listings for metabolic and cancer medicines from 965 seemingly noncompliant websites, with 126 sites marketing products in both categories, suggesting counterfeiters share infrastructure across very different therapeutic areas.

The online market for unapproved, counterfeit, and illegally marketed medicines is not an offshore problem beyond the reach of U.S. policy. Much of the internet infrastructure used by drug sellers is provided by U.S.-based companies, subject to U.S. law, and thus well-positioned to act.

Category	Seemingly noncompliant domains	Frequently used domain name registrars	Example websites (see appendix for screenshots)
Cancer medicines	232	GoDaddy (USA): 23% with 54 domains Rebel (Canada): 6% with 15 domains	medsright.com (Fig. 1 – GoDaddy) mountainside-medical.com (Fig. 2 – GoDaddy) medsprimehub.com (Fig. 3 – GoDaddy) publicpill.com (Fig. 4 – Rebel.com)
Metabolic disease	859	GoDaddy (USA): 19% with 154 domains Namecheap (USA): 10% with 90 domains	lyzelabs.com (Fig. 5 – GoDaddy) healthrx.com (Fig. 6 – GoDaddy) nasserpharmacy.com (Fig. 7 – GoDaddy) enhancedbiolabs.com (Fig. 8 – Namecheap Inc) midwestpeptide.com (Fig. 9 – Namecheap Inc) peptuvia.com (Fig. 10 – Namecheap Inc)
Investigational Drugs	170	GoDaddy (USA): 21% with 35 domains Namecheap (USA): 11% with 19 domains	cellpeptides.com (Fig. 11 – GoDaddy) sciencepeptideslab.com (Fig. 12 – GoDaddy) helixpep.com (Fig. 13 – GoDaddy)

Domains appear to be hosted at the registrar shown; percentages are shares of illegal domains in that category. Figure numbers refer to the screenshots on page 10.

But the numbers alone tell an incomplete story. It is not surprising to see GoDaddy and Namecheap hosting large percentages of domain names found in Rx Watchdog, given they are reportedly the two

largest domain name registrars globally.²⁴ What matters more is domain name registrars' responsiveness to notifications and abuse complaints citing domains that are being used to sell pharmaceutical products in ways violating U.S. law.

ASOP Global members report mixed results when it comes to registrar responsiveness to abuse complaints. GoDaddy and Namecheap have historically acted promptly on credible notices involving specific types of illegal online pharmacy activity. This is commendable. However, the responsiveness of these prominent registrars shifts when it comes to investigational new drugs and "research use only" sellers. More on this below.

Other registrars, however, have proven consistently unresponsive. ASOP members report the below registrars regularly refuse to act on complaints related to domains being used for illegal online drug sales:

- WEDOS Internet, a.s.;
- NICENIC INTERNATIONAL GROUP CO.;
- HOSTINGER operations, UAB;
- NameSilo, LLC;
- Hosting Concepts B.V. d/b/a Registrar.eu;
- PakNIC (Pvt.) Limited t/a Paknic; and
- Cloudflare

Some ASOP Global members have deprioritized sending notifications and abuse complaints to these registrars, recognizing that further notifications are unlikely to yield results.

Importantly, domain name registrars appear to be reluctant – if not outright resistant – to taking action on complaints related to domains being used to sell unapproved, "research use only" molecules, including those considered by FDA as investigational new drugs (INDs). Online sales of INDs and "research use only" products are a growing area of patient safety risk, involve clear violations of U.S. law, and thus deserve attention and swift action by domain name registrars upon notification of this abuse activity.^{25,26} ASOP Global urges attention to this increasingly popular and risky new category of illegal online drug sales.

Specifically, we ask USTR to encourage all domain name registrars to move beyond reactive, case-by-case responses and adopt proactive policies, including:

- Verification procedures for domains used to sell prescription drugs, INDs, and "research use only" products,
- Improved channels for reporting violations, and

²⁴ Domain State, Domain Name Registrar Stats, 2026. Available at: <https://www.domainstate.com/registrar-stats.html>

²⁵ FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, 2026. Available at: <https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss>

²⁶ Marshall et al. Letter Alerting National Security Council to Exploitation of FDA Approved Drugs by China Supply Chain, 2026. Available at: <https://www.alabamaag.gov/wp-content/uploads/2026/09/2026.09.17-Letter-to-Sec.-Rubio-re-GLPs.pdf>

- Safeguards against repeat offenders who simply re-register or transfer the domain to another domain name registrar upon investigation or suspension.

Marketplaces & Social Media

Beyond domain registrars, social media platforms and online marketplaces play a significant role in the illegal online sale of medicines. ASOP Global members report a notable shift in how counterfeit pharmaceutical products are offered on these platforms. Openly visible listings on platforms such as Facebook Marketplace and Instagram have increasingly given way to closed silos: disappearing 24-hour stories on Facebook and Instagram and invite-only seller groups on WhatsApp and Telegram. Fewer illicit offers may now be visible on the open internet, but this is likely to reflect sellers moving to less transparent channels rather than leaving the market. In these closed environments, traditional enforcement tools such as takedowns are far less effective, and investigators struggle to detect and monitor suspicious activity at all.

Even where listings remain visible and notice-and-takedown processes exist, platform responsiveness is uneven and often too slow to protect patients. Our members report:

- **X, Telegram, and WhatsApp:** Enforcement on these platforms is very limited, if it occurs at all. Each carries a persistent backlog of hundreds of pending takedown requests.
- **Facebook:** Removes reported listings in nearly every case, with a 96% success rate for one member, but the process is slow. That member's year-to-date removal rate is just 39%, which shows how far takedowns lag behind reporting.
- **Anoonturi.ro (Romanian online marketplace):** It has resisted takedown notices entirely.
- **IndiaMART:** Enforcement compliance is generally considered good, yet fraudulent offers persist, and open notice volumes remain substantial. Human health products seem to take priority over animal health products, so the latter tend to be less compliant despite the same regulatory or counterfeiting concerns. A major challenge highlighted several times over the years is that there are no penalties for repeat offenders who offer counterfeits, and the platform still refuses to take any accountability for the content posted. The platform is also unresponsive to brands' requests to collaborate on issues affecting patient safety. There is roughly a 50/50 mix of suspected counterfeit and diverted products being sold, including oncology injectables and vaccines (prescription only).
- **TradeIndia:** Similar to IndiaMART, there does not appear to be any sort of internal policy to deal with repeat sales of counterfeit or prohibited products. TradeIndia is also not responsive to requests made by rightsholders to collaborate on issues impacting patient safety. The marketplace offers a mix of suspected counterfeit and diverted (prescription only) medications, including oncology injectables, vaccines, and biosimilars.
- **Pinduoduo/PDD (China):** A major social e-commerce platform in China that has a low entry threshold for merchants, allowing illicit sellers to easily post counterfeit products for sale. While the platform boasts proactive measures involving the removal of millions of suspicious ads/blocking links, the algorithms used still enable high-volume sellers to gain visibility

regardless of the nature of their product. Flash sales contribute to this, as items are only active for a short period of time, making identification and enforcement a challenge. With limited opportunity for brands to really assess what is being posted, sellers can easily get away with selling counterfeit goods with no accountability.

- **Tokopedia (Indonesia):** Continues to facilitate a large volume of problematic listings without taking meaningful action to curb the activity. While individual listings are removed, they quickly resurface. ASOP members report having submitted 10,000+ reports of individual listings to the platform in the past year.

Identification is a further obstacle. Because sellers rely on stock images and often won't engage or share more information, it remains hard to tell diverted medicine from counterfeit product. Members see the same problems across Taobao, Tmall, and Exporters India.

Economic Impact

As a result of counterfeit pharmaceuticals purchased online, negative health outcomes and the costs to pharmaceutical companies and the healthcare system remain substantial. The IQVIA Institute for Human Data Science estimated that 12.6% of illegal online drug purchases produce adverse outcomes. These outcomes contribute an additional \$67 billion in costs to the U.S. health system and result in an estimated loss of \$34 billion for legitimate pharmaceutical businesses.²⁷ Given the continued growth of illegal online drug sales since these estimates were published, the actual figures in 2026 are likely significantly higher.

Policy Recommendations and Actions


ASOP Global respectfully urges USTR to incorporate the following actions into its 2026 Notorious Markets review and related engagement with government and private-sector partners.

1. USTR should continue to identify illegal online drug sellers in the Notorious Markets List and recognize that their harms extend beyond intellectual property infringement to public health. As discussed above, their conduct puts patients at risk of receiving falsified, substandard, or unapproved medicines, warranting higher-priority attention in USTR's review.
2. USTR should coordinate closely with FDA, the National Security Council, and other enforcement partners on the high-risk categories. Particular attention is warranted for the counterfeit and unapproved versions of FDA-approved drugs, products marketed "for research purposes only," and investigational new drugs like retatrutide.
3. USTR should recognize AI-facilitated illegal online drug sales in Notorious Markets evaluations and encourage online intermediaries to adopt effective safeguards.

²⁷ IQVIA Institute, Assessing the Impact of Illegal Online Pharmacies in the U.S., 2023. Available at: <https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-impact-of-illegal-online-pharmacies-in-the-us>

4. USTR should support consumer education that closes the awareness gap and directs consumers to verified legitimate pharmacies. The awareness gap described above leaves consumers vulnerable to counterfeit or substandard medicines and related harm.
5. USTR may wish to consider ecosystem-level monitoring data, including Rx Watchdog. ASOP Global would welcome the opportunity to provide a dashboard walkthrough. The Appendix illustrates Rx Watchdog's findings, and a live walkthrough could offer additional context.

Respectfully,

A handwritten signature in dark ink, reading "S. Leigh Verbois PhD". The signature is written in a cursive, flowing style. Below the signature is a horizontal line.

S. Leigh Verbois, PhD
ASOP Global Board of Directors, Chair

APPENDIX

Sample sites from each category, followed by social media listings. Figure numbers match the table on page 5.

Cancer medicines

ASOP GLOBAL | ALLIANCE FOR SAFE ONLINE PHARMACIES




Figure 1. medsright.com




Figure 2. mountain-side-medical.com

ASOP GLOBAL | ALLIANCE FOR SAFE ONLINE PHARMACIES




Figure 3. medsprimehub.com




Figure 4. publicpill.com

Metabolic disease




Figure 5. Lyze Labs




Figure 6. www.healthrx.com




Figure 9. midwestpeptide.com




Figure 10. peptuvia.com

Investigational Drugs

cellpeptides.com/product/buy-retatrutide/

🔍

☆

inks

Congress/Admin Li...

🇺🇸 Appropriations Stat...

🇬🇧 limit strangle hold o...

🇧🇪 List of U.S. Congress...

🇬🇪 employers remove...

🇺🇸 1-2 day shipping in USA.

🇬🇧 Made in ISO 9001:2015 certified lab

Cell Peptides

Peptides ▾

Bestsellers

Knowledgebase

3rd-Party Tests

Peptide Calculator

Search...

🔍

👤

🛒

+

RETATRUTIDE

Cell Peptides

Parity: 99%

For research use only

5mg

RETATRUTIDE

\$89.00 – \$169.00

🛡️ Laboratory-grade quality

📊 ≥ 99% purity

🚚 Next-day shipping

Retatrutide

Retatrutide is a triple agonist peptide that targets three different kinds of hormone receptors. These are glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This distinguishes it from other agonists that target just one or two receptors and forms the basis of research into its pharmacological properties. [1] This topic is important in metabolic and cardiometabolic research, as it activates all three receptor systems. Studies are being conducted to understand how the signaling systems of the three receptors may help analyze the processes associated with energy balance and metabolic control. Other areas of research include lipid metabolism and liver-related metabolic pathways. Ongoing research also examines the GIP, GLP-1, and glucagon receptor systems to better understand how these metabolic pathways interact and contribute to the regulation of energy balance and metabolic homeostasis.

Amount

\$89.00

Clear

5mg

▼

-

1

+

Add To Cart

Buy more and save

3+ vials	3% off
5+ vials	5% off
10+ vials	9% off

Price per vial

\$89.00

Selected quantity total

\$89.00

Each product or variation qualifies separately.

Figure 11. cellpeptides.com

→

🏠

sciencepeptideslab.com/collections/all?page=7

🔍

Retatrutide

10 mg

Batch No. 005

27-06-2025

RETATRUTIDE

10MG VIAL

\$75.00 USD

CAGRILINTIDE

10 mg

Batch No.003

29-06-2025

CAGRILINTIDE

10MG VIAL

\$92.00 USD

Bimagrumab

10 mg

Batch No.003

23-01-2026

BIMAGRUMAB

(BYM338) 10MG

\$8,297.00 USD

Figure 12. sciencepeptideslab.com

16




Figure 13. helixpep.com

Social Media Listings




Figure 14. Oncomed Pharmacy post offering Sorafenib (oncology drug), via social media.

embarkpeptides Embark Peptides is a locally owned small business offering research peptides and research compounds, including Reta GLP-3, GHK-Cu, KPV, MOTS-C, Tesamorelin, NAD+, and bacteriostatic water for research purposes.

We created Embark Peptides with a simple goal: to build something local, personal, and centered around quality.

As a small business, every order, message, referral, and share truly means something to us. We're incredibly grateful for everyone who has supported us and helped us grow along the way. 🐻

Thank you for choosing Embark Peptides and being part of our journey. ❤️

September 21

Figure 15. Embark Peptides selling unapproved drugs (retatrutide) and emerging molecules not vetted for safety in human use, via social media.

Posts florenziahealthcare Enzalutamide Capsules 40 mg Follow

A targeted Anti-Androgen Therapy for the management of advanced prostate cancer.

◆ **Indications:**
FLOENZA-40 is indicated for:
• Castration-Resistant Prostate Cancer (CRPC)
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

◆ **Product Highlights:**
✓ Enzalutamide Capsules 40 mg
✓ 28 Capsules
✓ Oral Dosage Form
✓ Manufactured under stringent quality standards
✓ For use only under medical supervision

◆ **Meet Us at IPHEX 2026**

We invite pharmaceutical partners, distributors, importers and healthcare professionals to connect with Florenzia Healthcare and explore our oncology portfolio.

📍 Hall-4 | Stall No. 4E-12
📅 IPHEX 2026

Let's connect and explore opportunities for global pharmaceutical partnerships.

📞 Contact: +91-9968996869
✉ Email: info@florenziahealthcare.com
🌐 Website: www.florenziahealthcare.com

Committed to Quality. Focused on Global Healthcare.

#FlorenziaHealthcare #FLOENZA40 #Enzalutamide #ProstateCancer #Oncology #CancerCare #AnticancerMedicine #OncologyDrugs #Pharmaceuticals #PharmaManufacturing #PharmaExport #GlobalHealthcare #PharmaceuticalIndustry #IPHEX2026 #IPHEX #PharmaPartners #HealthcareInnovation #CRPC #mHSPC

August 8

florenziahealthcare

Visit us at **IPHEX 2026**
HALL-4
Stall No. 4E-12

Rx FLOENZA-40
Enzalutamide Capsules 40 mg

A potent Anti-Androgen Therapy for Advanced Prostate Cancer

INDICATIONS
FLOENZA-40 is indicated for:
• Castration-Resistant Prostate Cancer (CRPC)
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

KEY BENEFITS

28 Capsules	Enzalutamide Capsules 40 mg	Oral Dosage	WHO-GMP Certified Manufacturing	For use only under medical supervision
-------------	-----------------------------	-------------	---------------------------------	--

QUALITY YOU CAN TRUST | STRONGEST QUALITY ASSURANCE | ADVANCED MANUFACTURING | GLOBAL STANDARDS GLOBAL IMPACT | COMMITTED TO BETTER OUTCOMES

+91-9968996869 | info@florenziahealthcare.com | www.florenziahealthcare.com

florenziahealthcare FLOENZA-40: Enzalutamide Capsules 40 mg

A targeted Anti-Androgen Therapy for the management of advanced prostate cancer.

◆ **Indications:**
FLOENZA-40 is indicated for:
• Castration-Resistant Prostate Cancer (CRPC)
• Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

◆ **Product Highlights:**
✓ Enzalutamide Capsules 40 mg
✓ 28 Capsules

Figures 16 and 17. India-based Florenzia Healthcare selling oncology drugs online.